tailieunhanh - Báo cáo y học: " Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients | Raffa et al. BMC Psychiatry 2011 11 124 http 1471-244X 11 124 BMC Psychiatry RESEARCH ARTICLE Open Access Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients 1 1 1 Monia Raffa Fatma Atig Ahmed Mhalla Abdelhamid Kerkeni and Anwar Mechri Abstract Background The aim of this study was to determine glutathione levels and antioxidant enzyme activities in the drug-naive first-episode patients with schizophrenia in comparison with healthy control subjects. Methods It was a case-controlled study carried on twenty-three patients 20 men and 3 women mean age years recruited in their first-episode of schizophrenia and 40 healthy control subjects 36 men and 9 women mean age years . In patients the blood samples were obtained prior to the initiation of neuroleptic treatments. Glutathione levels total glutathione GSHt reduced glutathione GSHr and oxidized glutathione GSSG and antioxidant enzyme activities superoxide dismutase SOD glutathione peroxidase GPx catalase CAT were determined by spectrophotometry. Results GSHt and reduced GSHr were significantly lower in patients than in controls whereas GSSG was significantly higher in patients. GPx activity was significantly higher in patients compared to control subjects. CAT activity was significantly lower in patients whereas the SOD activity was comparable to that of controls. Conclusion This is a report of decreased plasma levels of GSHt and GSHr and impaired antioxidant enzyme activities in drug-naive first-episode patients with schizophrenia. The GSH deficit seems to be implicated in psychosis and may be an important indirect biomarker of oxidative stress in schizophrenia early in the course of illness. Finally our results provide support for further studies of the possible role of antioxidants as neuroprotective therapeutic strategies for schizophrenia from early stages. Background There is strong evidence that